Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cetrorelix Acetate

FDA-approved product (powder, subcutaneous), marketed as Cetrorelix Acetate, Cetrotide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cetrorelix Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Ovulation Inhibition
  • Positive regulation of ovulation

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Anti-gonadotropin-releasing hormones
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cetrorelix Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cetrorelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for in Vitro Fertilization: a Prospective Comparative Observational Study

    NCT07732348 · start 2026-09

    Registered record
    Registry ID
    NCT07732348
    Conditions
    Infertility, Female; Ovulation Induction
    Interventions
    Ganirelix; Cetrorelix; Medroxyprogesterone Acetate; Dienogest; Micronized Progesterone; Linzagolix
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2026-12
    Enrolment
    195

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female; Ovulation Induction
    InterventionGanirelix; Cetrorelix; Medroxyprogesterone Acetate; Dienogest +2 more
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Trial Comparing Subcutaneous Natural Progesterone (Prolutex) vs. Cetrorelix Acetate for Luteinizing Hormone Surge Suppression in Freeze-All IVF Cycles.

    NCT07350317 · start 2026-01

    Registered record
    Registry ID
    NCT07350317
    Conditions
    Assisted Reproductive Techniques
    Interventions
    Control Group (A):; Test Group (B):
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-01
    Completion
    2027-02
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAssisted Reproductive Techniques
    InterventionControl Group (A):; Test Group (B):
    PhasePhase 4
    Registry statusNot yet recruiting

  • Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!

    NCT06608186 · start 2024-10-01

    Registered record
    Registry ID
    NCT06608186
    Conditions
    PCOS (Polycystic Ovary Syndrome)
    Interventions
    Cetrorelix drug; Drospirenone drug
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2024-10-01
    Completion
    2025-01-19
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPCOS (Polycystic Ovary Syndrome)
    InterventionCetrorelix drug; Drospirenone drug
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes

    NCT06396390 · start 2024-08-01

    Registered record
    Registry ID
    NCT06396390
    Conditions
    IVF; Fertility Issues; Infertility
    Interventions
    Progestin; GnRH antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-08-01
    Completion
    2026-08-01
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIVF; Fertility Issues; Infertility
    InterventionProgestin; GnRH antagonist
    PhasePhase 4
    Registry statusUnknown

  • Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF

    NCT06023602 · start 2024-02-27

    Registered record
    Registry ID
    NCT06023602
    Conditions
    Infertility
    Interventions
    Generic cetrorelix acetate; Reference cetrorelix acetate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-02-27
    Completion
    2025-12-01
    Enrolment
    1,338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionGeneric cetrorelix acetate; Reference cetrorelix acetate
    PhaseNot applicable
    Registry statusRecruiting

  • Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome

    NCT06812559 · start 2023-12-01

    Registered record
    Registry ID
    NCT06812559
    Conditions
    Controlled Ovarian Hyperstimulation; Polycystic Ovarian Syndrome
    Interventions
    Progesterone; GnRH antagonist (Cetrorelix)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-12-01
    Completion
    2025-02-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionControlled Ovarian Hyperstimulation; Polycystic Ovarian Syndrome
    InterventionProgesterone; GnRH antagonist (Cetrorelix)
    PhaseNot recorded
    Registry statusCompleted

  • Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes

    NCT05972902 · start 2023-07-15

    Registered record
    Registry ID
    NCT05972902
    Conditions
    IVF
    Interventions
    Dydrogesterone; Cetrorelix acetate; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-07-15
    Completion
    2023-12-31
    Enrolment
    387

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIVF
    InterventionDydrogesterone; Cetrorelix acetate; Triptorelin
    PhasePhase 3
    Registry statusUnknown

  • Acupuncture in the Freeze-all IVF Cycle

    NCT04931355 · start 2023-06-01

    Registered record
    Registry ID
    NCT04931355
    Conditions
    Acupuncture; Female Infertility
    Interventions
    Acupuncture; Western medicine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-06-01
    Completion
    2024-12-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcupuncture; Female Infertility
    InterventionAcupuncture; Western medicine
    PhaseNot applicable
    Registry statusUnknown

  • Progesterone Primed Ovarian Stimulation Protocol Versus Antagonist Protocol for PCO Patient

    NCT05847660 · start 2023-06-01

    Registered record
    Registry ID
    NCT05847660
    Conditions
    Polycystic Ovary Syndrome; Infertility; IVF
    Interventions
    Progesterone antagonist; conventional antagonist protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-06-01
    Completion
    2024-07-01
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome; Infertility; IVF
    InterventionProgesterone antagonist; conventional antagonist protocol
    PhaseNot applicable
    Registry statusUnknown

  • Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles

    NCT05767086 · start 2023-03-15

    Registered record
    Registry ID
    NCT05767086
    Conditions
    Infertility
    Interventions
    Gonadotropin releasing hormone antagonist (Cetrotide); Medroxyprogesterone Acetate (Tarlusal); Dydrogesterone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-03-15
    Completion
    2024-09-30
    Enrolment
    297

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionGonadotropin releasing hormone antagonist (Cetrotide); Medroxyprogesterone Acetate (Tarlusal); Dydrogesterone
    PhaseNot applicable
    Registry statusCompleted

  • Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization

    NCT06191809 · start 2023-02-14

    Registered record
    Registry ID
    NCT06191809
    Conditions
    IVF
    Interventions
    Controlled Ovarian Stimulation Protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-02-14
    Completion
    2024-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIVF
    InterventionControlled Ovarian Stimulation Protocol
    PhaseNot applicable
    Registry statusUnknown

  • PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial

    NCT06868576 · start 2023-01-03

    Registered record
    Registry ID
    NCT06868576
    Conditions
    PPOS; GnRH Antagonist; Assisted Reproductive Techniques
    Interventions
    Dydrogesterone Oral Tablet; Cetrorelix (Cetrotide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-01-03
    Completion
    2025-02-28
    Enrolment
    328

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPPOS; GnRH Antagonist; Assisted Reproductive Techniques
    InterventionDydrogesterone Oral Tablet; Cetrorelix (Cetrotide)
    PhasePhase 3
    Registry statusCompleted

  • DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation

    NCT04616729 · start 2022-11-01

    Registered record
    Registry ID
    NCT04616729
    Conditions
    Breast Cancer Female
    Interventions
    Triptorelin 3.75 MG Injection; Transvaginal oocyte retrieval; Triptorelin Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2022-11-01
    Completion
    2025-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female
    InterventionTriptorelin 3.75 MG Injection; Transvaginal oocyte retrieval; Triptorelin Injection
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Effect of GH on the Blastocyst Euploid Rate in AMA Patients

    NCT05447208 · start 2022-08-01

    Registered record
    Registry ID
    NCT05447208
    Conditions
    Preimplantation Genetic Testing; Growth Hormone; Age, Parental
    Interventions
    Growth Hormone; GnRH antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-08-01
    Completion
    2026-12-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreimplantation Genetic Testing; Growth Hormone; Age, Parental
    InterventionGrowth Hormone; GnRH antagonist
    PhasePhase 3
    Registry statusRecruiting

  • Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol

    NCT04989348 · start 2021-08-04

    Registered record
    Registry ID
    NCT04989348
    Conditions
    IVF
    Interventions
    Gonadotrophin releasing hormone antagonist protocol; Progestin-primed ovarian stimulation protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-08-04
    Completion
    2024-02-20
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIVF
    InterventionGonadotrophin releasing hormone antagonist protocol; Progestin-primed ovarian stimulation protocol
    PhaseNot applicable
    Registry statusCompleted